{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:46:40Z","timestamp":1790264800258,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myelofibrosis (MF) belongs to the family of classic Philadelphia-negative myeloproliferative neoplasms (MPNs). It can be primary myelofibrosis (PMF) or secondary myelofibrosis (SMF) evolving from polycythemia vera (PV) or essential thrombocythemia (ET). Despite the differences, PMF and SMF patients are currently managed in the same way, and prediction of survival is based on the same clinical and genetic features. In the last few years, interest has grown concerning the ability of gene expression profiles (GEPs) to provide valuable prognostic information. Here, we studied the GEPs of granulocytes from 114 patients with MF, using a microarray platform to identify correlations with patient characteristics and outcomes. Cox regression analysis led to the identification of 201 survival-related transcripts characterizing patients who are at high risk for death. High-risk patients identified by this gene signature displayed an inferior overall survival and leukemia-free survival, together with clinical and molecular detrimental features included in contemporary prognostic models, such as the presence of high molecular risk mutations. The high-risk group was enriched in post-PV and post-ET MF and JAK2V617F homozygous patients, whereas pre-PMF was more frequent in the low-risk group. These results demonstrate that GEPs in MF patients correlate with their molecular and clinical features, particularly their survival, and represent the proof of concept that GEPs might provide complementary prognostic information to be applied in clinical decision making.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003614","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:44:57Z","timestamp":1614962697000},"page":"1452-1462","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-4181","authenticated-orcid":false,"given":"Sebastiano","family":"Rontauroli","sequence":"first","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-7854","authenticated-orcid":false,"given":"Sara","family":"Castellano","sequence":"additional","affiliation":[{"name":"Center for Genome Research,"},{"name":"Department of Medical and Surgical Sciences, and"},{"name":"PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation for Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero Universitaria Careggi, Florence, Italy;"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Excellence Center Denothe, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zini","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-5944","authenticated-orcid":false,"given":"Elisa","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Genovese","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-0818","authenticated-orcid":false,"given":"Chiara","family":"Carretta","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Parenti","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fantini","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Mallia","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Tavernari","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sartini","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Mirabile","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Mannarelli","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation for Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero Universitaria Careggi, Florence, Italy;"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Excellence Center Denothe, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gesullo","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation for Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero Universitaria Careggi, Florence, Italy;"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Excellence Center Denothe, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Pacilli","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation for Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero Universitaria Careggi, Florence, Italy;"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Excellence Center Denothe, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6575-8766","authenticated-orcid":false,"given":"Daniela","family":"Pietra","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-9504","authenticated-orcid":false,"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy;"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salmoiraghi","sequence":"additional","affiliation":[{"name":"Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mora","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ospedale ASST Sette Laghi, University of Insubria, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Villani","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, Foundation IRCCS Policlinico San Matteo, Pavia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Grilli","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-2289","authenticated-orcid":false,"given":"Vittorio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, Foundation IRCCS Policlinico San Matteo, Pavia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-7192","authenticated-orcid":false,"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, Foundation IRCCS Policlinico San Matteo, Pavia, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ospedale ASST Sette Laghi, University of Insubria, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy;"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy;"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Bicciato","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tagliafico","sequence":"additional","affiliation":[{"name":"Center for Genome Research,"},{"name":"Department of Medical and Surgical Sciences, and"},{"name":"PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation for Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliero Universitaria Careggi, Florence, Italy;"},{"name":"Department of Experimental and Clinical Medicine, University of Florence, Excellence Center Denothe, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-6110","authenticated-orcid":false,"given":"Rossella","family":"Manfredini","sequence":"additional","affiliation":[{"name":"Centre for Regenerative Medicine, Life Sciences Department,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"issue":"20","key":"2021030516341362500_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [published correction appears in Blood. 2016;128(3):462-463]","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2021030516341362500_B2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"15","key":"2021030516341362500_B3","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2021030516341362500_B4","doi-asserted-by":"crossref","first-page":"a034876","DOI":"10.1101\/cshperspect.a034876","article-title":"The molecular genetics of myeloproliferative neoplasms","volume":"10","author":"Marneth","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"2021030516341362500_B5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"issue":"12","key":"2021030516341362500_B6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2021030516341362500_B7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"2021030516341362500_B8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"issue":"4","key":"2021030516341362500_B9","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2013.101733","article-title":"The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis","volume":"99","author":"Hern\u00e1ndez-Boluda","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"2021030516341362500_B10","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"2021030516341362500_B11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"2021030516341362500_B12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"2021030516341362500_B13","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021030516341362500_B14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"7633","key":"2021030516341362500_B15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature20598","article-title":"A 17-gene stemness score for rapid determination of risk in acute leukaemia","volume":"540","author":"Ng","year":"2016","journal-title":"Nature"},{"issue":"16","key":"2021030516341362500_B16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMoa031046","article-title":"Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia","volume":"350","author":"Bullinger","year":"2004","journal-title":"N Engl J Med"},{"issue":"28","key":"2021030516341362500_B17","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1200\/JCO.2012.45.5626","article-title":"Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes","volume":"31","author":"Pellagatti","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021030516341362500_B18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1182\/blood-2008-10-187203","article-title":"Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome","volume":"114","author":"Mills","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2021030516341362500_B19","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood-2017-05-783050","article-title":"Gene expression and risk of leukemic transformation in myelodysplasia [published correction appears in Blood. 2018;132(8):869-875]","volume":"130","author":"Shiozawa","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2021030516341362500_B20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol"},{"issue":"10","key":"2021030516341362500_B21","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"issue":"13","key":"2021030516341362500_B22","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1182\/blood-2013-12-544197","article-title":"miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155\/JARID2 axis in abnormal megakaryopoiesis","volume":"124","author":"Norfo","year":"2014","journal-title":"Blood"},{"issue":"6871","key":"2021030516341362500_B23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van \u2019t Veer","year":"2002","journal-title":"Nature"},{"issue":"24","key":"2021030516341362500_B24","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2021030516341362500_B25","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/bjh.14838","article-title":"Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons","volume":"182","author":"Mudireddy","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2021030516341362500_B26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2018.05.013","article-title":"Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and\/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study","volume":"55","author":"Palandri","year":"2018","journal-title":"Semin Hematol"},{"issue":"2","key":"2021030516341362500_B27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis biology and contemporary management","volume":"191","author":"Gangat","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"2021030516341362500_B28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"2021030516341362500_B29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-018-0109-0","article-title":"Myelofibrosis treatment algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"13","key":"2021030516341362500_B30","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2021030516341362500_B31","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2021030516341362500_B32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021030516341362500_B33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5152\/ejbh.2017.3636","article-title":"Gene expression profiling in breast cancer and its effect on therapy selection in early-stage breast cancer","volume":"13","author":"G\u00fcler","year":"2017","journal-title":"Eur J Breast Health"},{"issue":"12","key":"2021030516341362500_B34","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2021030516341362500_B35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.25351","article-title":"20+ Years and alive with primary myelofibrosis: phenotypic signature of very long-lived patients","volume":"94","author":"Penna","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/5\/1452\/1801853\/advancesadv2020003614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/5\/1452\/1801853\/advancesadv2020003614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:45:20Z","timestamp":1614962720000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/5\/1452\/475394\/Gene-expression-profile-correlates-with-molecular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,3,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003614","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]}}}